These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8085253)

  • 1. SC-49992--a potent and specific inhibitor of platelet aggregation.
    Nicholson NS; Panzer-Knodle SG; King LW; Taite BB; Keller BT; Tjoeng FS; Engleman VW; Giorgio TD; Feigen LP
    Thromb Res; 1994 Jun; 74(5):523-35. PubMed ID: 8085253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
    J Pharmacol Exp Ther; 1991 Mar; 256(3):876-82. PubMed ID: 2005585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
    Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
    Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mimetic of the RGDF-peptide [arginine-glycine-aspartic acid-phenylalanine] blocks aggregation and flow-induced platelet deposition on severely injured stenotic arterial wall. Effects on different animal models and in humans.
    Pueyo C; Badimon JJ; Royo T; Feigen LP; Badimon L
    Thromb Res; 1996 Jan; 81(1):101-12. PubMed ID: 8747525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.
    Zablocki JA; Miyano M; Garland RB; Pireh D; Schretzman L; Rao SN; Lindmark RJ; Panzer-Knodle SG; Nicholson NS; Taite BB
    J Med Chem; 1993 Jun; 36(13):1811-9. PubMed ID: 8515420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents.
    Bovy PR; Tjoeng FS; Rico JG; Rogers TE; Lindmark RJ; Zablocki JA; Garland RB; McMackins DE; Dayringer H; Tóth MV
    Bioorg Med Chem; 1994 Sep; 2(9):881-95. PubMed ID: 7712124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human platelet aggregation by GR91669, a prototype fibrinogen receptor antagonist.
    Foster MR; Hornby EJ; Brown S; Hann M; Kitchin J; Pike N; Ward P
    Thromb Res; 1994 Aug; 75(3):269-84. PubMed ID: 7992238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.
    Imura Y; Stassen JM; Bunting S; Stockmans F; Collen D
    Blood; 1992 Sep; 80(5):1247-53. PubMed ID: 1515641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent.
    Nicholson NS; Panzer-Knodle SG; Salyers AK; Taite BB; King LW; Miyano M; Gorczynski RJ; Williams MH; Zupec ME; Tjoeng FS
    Thromb Res; 1991 Jun; 62(5):567-78. PubMed ID: 1896969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
    Huang TF; Liu CZ; Ouyang CH; Teng CM
    Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation.
    Panzer-Knodle S; Taite BB; Mehrotra DV; Nicholson NS; Feigen LP
    J Pharmacol Toxicol Methods; 1993 Sep; 30(1):47-53. PubMed ID: 8241546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs.
    Foster MR; Hornby EJ; Brown S; Kitchin J; Hann M; Ward P
    Thromb Res; 1993 Nov; 72(3):231-45. PubMed ID: 8303662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitro.
    Samanen J; Ali F; Romoff T; Calvo R; Sorenson E; Vasko J; Storer B; Berry D; Bennett D; Strohsacker M
    J Med Chem; 1991 Oct; 34(10):3114-25. PubMed ID: 1920361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
    J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
    Andronati SA; Karaseva TL; Krysko AA
    Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New RGD analogue inhibits human platelet adhesion and aggregation and eliminates platelet deposition on canine vascular grafts.
    Rubin BG; McGraw DJ; Sicard GA; Santoro SA
    J Vasc Surg; 1992 Apr; 15(4):683-91; discussion 691-2. PubMed ID: 1560559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
    Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
    Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Asp-carboxylate of RGDX mimetics and the platelet GP IIb-IIIa receptor.
    Zablocki JA; Miyano M; Rao SN; Panzer-Knodle S; Nicholson N; Feigen L
    J Med Chem; 1992 Dec; 35(26):4914-7. PubMed ID: 1479591
    [No Abstract]   [Full Text] [Related]  

  • 20. Aminopeptidase resistant Arg-Gly-Asp analogs are stable in plasma and inhibit platelet aggregation.
    Fok KF; Panzer-Knodle SG; Nicholson NS; Tjoeng FS; Feigen LP; Adams SP
    Int J Pept Protein Res; 1991 Aug; 38(2):124-30. PubMed ID: 1783488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.